My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 9 Next >
Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF ≥40% at AHA 2024
From Bayer
Via Business Wire
Bayer’s Receives FDA Clearance for MEDRAD® Centargo CT Injection System
From Bayer
Via Business Wire
Bayer and Liveo Research Launch First-of-its-Kind Blister Packaging with Improved Environmental Footprint
From Bayer
Via Business Wire
U.S. Food and Drug Administration (FDA) accepts New Drug Application for elinzanetant
From Bayer
Via Business Wire
Bayer and MOMA Therapeutics Enter Collaboration and License Agreement in Oncology
From Bayer
Via Business Wire
BlueRock Therapeutics’ Investigational Cell Therapy Bemdaneprocel for Parkinson’s Disease Shows Positive Data at 24-Months
From Bayer
Via Business Wire
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Indication for NUBEQA® (darolutamide) in Metastatic Hormone-Sensitive Prostate Cancer
From Bayer
Via Business Wire
New Publication Evaluates Awareness of High Breast Density as a Risk Factor for Breast Cancer
From Bayer
Via Business Wire
Bayer, UPMC Magee-Women’s Hospital, PA Senate President Pro Tempore Kim Ward Collaborate to Bring Breast Health Care and Awareness to Pittsburgh Region’s Rural and Underserved Communities
From Bayer
Via Business Wire
ESMO 2024 Late-Breaking Data: Phase III ARANOTE Trial Shows NUBEQA® (darolutamide) Significantly Reduced Risk of Radiological Progression or Death in Metastatic Hormone-Sensitive Prostate Cancer
From Bayer
Via Business Wire
Bayer Consumer Health Welcomes Bayer 04 Leverkusen to Kick Off Historic Trophy Tour in the U.S. After Undefeated Bundesliga Season
From Bayer
Via Business Wire
Welcome to “Wita”: Claritin® Aims to Take the ‘Itch’ Out of Wichita, the #1 Allergy Capital in the U.S., Just in Time for Fall Allergy Season
From Bayer
Via Business Wire
Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause
From Bayer
Via Business Wire
New results from the Investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC
From Bayer
Via Business Wire
Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio Research at ESMO 2024
From Bayer
Via Business Wire
Bayer to Unveil New Data From Its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated With Menopause
From Bayer
Via Business Wire
ESC 2024: Late-Breaking KERENDIA® (finerenone) Investigational Data Presented
From Bayer
Via Business Wire
ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data
From Bayer
Via Business Wire
Bayer starts Phase III Trial in Non-Small Cell Lung Cancer (NSCLC)
From Bayer
Via Business Wire
Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology
From Bayer
Via Business Wire
Fast, Stable, Secure: New Bayer Hardware Simplifies Farm Activities, Equipment Setup and Provides Increased Value to Farmers
From Bayer
Via Business Wire
The Journal of American Medical Association (JAMA) publishes Elinzanetant Phase III data
From Bayer
Via Business Wire
Bayer Initiates Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients With Chronic Kidney Disease
From Bayer
Via Business Wire
Bayer and Alara Imaging Announce Collaboration
From Bayer
Via Business Wire
Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA® (finerenone) in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction
From Bayer
Via Business Wire
Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause
From Bayer
Via Business Wire
Bayer announces positive topline results for NUBEQA® (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC)
From Bayer
Via Business Wire
Bayer and Kroger Team Up with Luke Bryan and Feeding America to Improve Access to Nutritious Food
From Bayer
Via Business Wire
One A Day® Launches Science-Backed Cellular Aging Support Supplement
From Bayer
Via Business Wire
Bayer and Rad AI Announce Collaboration agreement
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.